Detalhe da pesquisa
1.
Multicentre, randomised, double-blind, placebo-controlled, proof of concept study of LSALT peptide as prevention of acute respiratory distress syndrome and acute kidney injury in patients infected with SARS-CoV-2 (COVID-19).
BMJ Open;
14(3): e076142, 2024 Mar 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-38490660